The researchers studied 26 patients who were suffering from discogenic lower back pain. Patients were followed up at 3, 6, and 12 months.
After 12 months, 21 out of 26 patients experienced statistically significant improvements in pain scores and impairment. The most dramatic improvements were seen in patients with higher stem cell counts.
The original publication can be found here: http://onlinelibrary.wiley.com/doi/10.1002/stem.1845/epdf
At Riordan Medical Institute, our doctors perform a procedure for degenerative disc disease that is similar to the one described in the Stem Cell Journal study.
However, we augment the BMAC injections with an amniotic tissue product developed by Dr. Riordan. It is a pliable tissue allograft (transplant) derived from human placental amnion, which contains over 100 growth factors and functions as a biologic structural matrix to facilitate and enhance tissue healing and repair. The inclusion of this product adds a new dimension to the tissue repair process that was successfully tested in the cited study.
We perform lumbar disc injections with BMAC and amniotic tissue product at RMI and therefore, we are encouraged to see an independent study published in a peer-reviewed scientific journal that concludes that a similar procedure is effective for patients suffering from discogenic lumbar back pain.
If you are suffering from degenerative disc disease and would like to be evaluated for treatment at RMI, the first step is to complete an online medical history. Once we receive it, our staff will contact you to answer general questions and to guide you through the rest of the evaluation process, which usually requires recent MRI images and an MRI report.
*Amniotic tissue is procured from contracted hospitals after normal, healthy births